New Results
Impact of Type II LRRK2 inhibitors on signalling and mitophagy
View ORCID ProfileAnna Tasegian, View ORCID ProfileFrancois Singh, View ORCID ProfileIan G Ganley, Alastair D Reith, View ORCID ProfileDario R Alessi
doi: https://doi.org/10.1101/2021.05.21.445132
Anna Tasegian
1Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
Francois Singh
1Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
Ian G Ganley
1Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
Alastair D Reith
2GlaxoSmithKline Pharmaceuticals R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK
Dario R Alessi
1Medical Research Council (MRC) Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK
Article usage
Posted May 25, 2021.
Impact of Type II LRRK2 inhibitors on signalling and mitophagy
Anna Tasegian, Francois Singh, Ian G Ganley, Alastair D Reith, Dario R Alessi
bioRxiv 2021.05.21.445132; doi: https://doi.org/10.1101/2021.05.21.445132
Subject Area
Subject Areas
- Biochemistry (11715)
- Bioengineering (8723)
- Bioinformatics (29129)
- Biophysics (14936)
- Cancer Biology (12049)
- Cell Biology (17359)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14144)
- Epidemiology (2067)
- Evolutionary Biology (18268)
- Genetics (12221)
- Genomics (16767)
- Immunology (11843)
- Microbiology (28014)
- Molecular Biology (11560)
- Neuroscience (60814)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4940)
- Plant Biology (10384)
- Synthetic Biology (2878)
- Systems Biology (7333)
- Zoology (1642)